tiprankstipranks
Evolent Health Inc. (DE:9EH)
NYSE:9EH
Germany Market
9EH
Evolent Health
RESEARCH TOOLSreports

Evolent Health (9EH) Stock Forecast & Price Target

1 Followers
See the Price Targets and Ratings of:

9EH Analyst Ratings

Moderate Buy
10Ratings
Moderate Buy
7 Buy
3 Hold
0 Sell
Based on 10 analysts giving stock ratings to
Evolent
Health
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

9EH Stock 12 Month Forecast

Average Price Target

€4.99
▲(97.88% Upside)
Based on 10 Wall Street analysts offering 12 month price targets for Evolent Health in the last 3 months. The average price target is €4.99 with a high forecast of €7.01 and a low forecast of €2.63. The average price target represents a 97.88% change from the last price of €2.52.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"€0","5":"€5","10":"€10","2.5":"€2.5","7.5":"€7.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":7.01407992,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€7.01</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4.9865724431250005,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€4.99</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2.63027997,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€2.63</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,2.5,5,7.5,10],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.66,4.841083070769231,5.022166141538461,5.203249212307693,5.384332283076923,5.565415353846154,5.7464984246153845,5.927581495384615,6.108664566153847,6.289747636923077,6.470830707692308,6.651913778461539,6.832996849230769,{"y":7.01407992,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.66,4.685120957163462,4.710241914326923,4.735362871490385,4.760483828653847,4.785604785817308,4.81072574298077,4.835846700144231,4.860967657307692,4.886088614471154,4.911209571634616,4.936330528798077,4.961451485961539,{"y":4.9865724431250005,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.66,4.50386769,4.3477353800000005,4.19160307,4.03547076,3.87933845,3.7232061400000003,3.56707383,3.41094152,3.2548092100000003,3.0986769,2.9425445900000002,2.7864122800000004,{"y":2.63027997,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":9.9,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.9,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.15,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.1,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.85,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.58,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.42,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.68,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.76,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.95,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.22,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.38,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.66,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target€7.01Average Price Target€4.99Lowest Price Target€2.63
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
RBC Capital Analyst forecast on DE:9EH
Ryan Halsted
RBC Capital
RBC Capital
€2.63
Hold
4.38%
Upside
Reiterated
07/08/26
Evolent Health (EVH) Receives a Hold from RBC Capital
Truist Financial Analyst forecast on DE:9EH
Jailendra Singh
Truist Financial
Truist Financial
€6.14
Hold
143.54%
Upside
Downgraded
06/30/26
Evolent Health: Near-Term Upside Seen as Limited; Hold Rating Reaffirmed with Unchanged $7 Price Target Amid Valuation and Policy Risks
William Blair Analyst forecast on DE:9EH
Ryan Daniels
William Blair
William Blair
―
Buy
―
Reiterated
05/15/26
Analysts' Top Healthcare Picks: ProMIS Neurosciences (PMN), Evolent Health (EVH)
Citi Analyst forecast on DE:9EH
Daniel Grosslight
Citi
Citi
€3.51→€4.82
Buy
91.36%
Upside
Reiterated
05/15/26
Evolent Health price target raised to $5.50 from $4 at CitiEvolent Health price target raised to $5.50 from $4 at Citi
Canaccord Genuity Analyst forecast on DE:9EH
Richard Close
Canaccord Genuity
Canaccord Genuity
€4.38→€5.26
Buy
108.75%
Upside
Reiterated
05/12/26
Evolent Health price target raised to $6 from $5 at CanaccordEvolent Health price target raised to $6 from $5 at Canaccord
TD Cowen Analyst forecast on DE:9EH
Charles Rhyee
TD Cowen
TD Cowen
€6.14→€7.01
Buy
178.34%
Upside
Reiterated
05/11/26
Analysts Offer Insights on Healthcare Companies: Evolent Health (NYSE: EVH), MoonLake Immunotherapeutics (NASDAQ: MLTX) and CAMP4 Therapeutics Corporation (NASDAQ: CAMP)
UBS Analyst forecast on DE:9EH
Kevin Caliendo
UBS
UBS
€4.38
Buy
73.96%
Upside
Reiterated
05/08/26
Evolent Health (EVH) Gets a Buy from UBS
KeyBanc Analyst forecast on DE:9EH
Matthew Gillmor CFA
KeyBanc
KeyBanc
―
Hold
―
Reiterated
05/08/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Evolent Health (NYSE: EVH), Zoetis (NYSE: ZTS) and ICU Medical (NASDAQ: ICUI)
BMO Capital Analyst forecast on DE:9EH
Sean Dodge
BMO Capital
BMO Capital
€3.07→€5.26
Buy
108.75%
Upside
Reiterated
05/08/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Needham Analyst forecast on DE:9EH
Matthew Shea
Needham
Needham
€3.51→€4.38
Buy
73.96%
Upside
Reiterated
05/07/26
Analysts Are Bullish on These Healthcare Stocks: Prime Medicine, Inc. (PRME), Evolent Health (EVH)
Oppenheimer Analyst forecast on DE:9EH
Michael Wiederhorn
Oppenheimer
Oppenheimer
―
Buy
―
Reiterated
03/20/26
Oppenheimer Reaffirms Their Buy Rating on Evolent Health (EVH)
J.P. Morgan Analyst forecast on DE:9EH
John Stansel
J.P. Morgan
J.P. Morgan
€4.38
Buy
73.96%
Upside
Reiterated
03/03/26
Evolent Health (EVH) Receives a Buy from J.P. Morgan
BTIG Analyst forecast on DE:9EH
David Larsen
BTIG
BTIG
€8.77→€7.01
Buy
178.34%
Upside
Reiterated
02/25/26
Evolent Health: Conservative Guidance and Elevated Reserves Set the Stage for 2026 Margin Upside and Support a Buy Rating
Stephens Analyst forecast on DE:9EH
Jeffrey Garro
Stephens
Stephens
€6.14
Buy
143.54%
Upside
Reiterated
02/25/26
Evolent Health (EVH) Gets a Buy from Stephens
Citizens JMP Analyst forecast on DE:9EH
Constantine Davides
Citizens JMP
Citizens JMP
€9.64→€8.77
Buy
247.92%
Upside
Reiterated
01/06/26
Evolent Health price target lowered to $10 from $11 at CitizensEvolent Health price target lowered to $10 from $11 at Citizens
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
RBC Capital Analyst forecast on DE:9EH
Ryan Halsted
RBC Capital
RBC Capital
€2.63
Hold
4.38%
Upside
Reiterated
07/08/26
Evolent Health (EVH) Receives a Hold from RBC Capital
Truist Financial Analyst forecast on DE:9EH
Jailendra Singh
Truist Financial
Truist Financial
€6.14
Hold
143.54%
Upside
Downgraded
06/30/26
Evolent Health: Near-Term Upside Seen as Limited; Hold Rating Reaffirmed with Unchanged $7 Price Target Amid Valuation and Policy Risks
William Blair Analyst forecast on DE:9EH
Ryan Daniels
William Blair
William Blair
―
Buy
―
Reiterated
05/15/26
Analysts' Top Healthcare Picks: ProMIS Neurosciences (PMN), Evolent Health (EVH)
Citi Analyst forecast on DE:9EH
Daniel Grosslight
Citi
Citi
€3.51→€4.82
Buy
91.36%
Upside
Reiterated
05/15/26
Evolent Health price target raised to $5.50 from $4 at CitiEvolent Health price target raised to $5.50 from $4 at Citi
Canaccord Genuity Analyst forecast on DE:9EH
Richard Close
Canaccord Genuity
Canaccord Genuity
€4.38→€5.26
Buy
108.75%
Upside
Reiterated
05/12/26
Evolent Health price target raised to $6 from $5 at CanaccordEvolent Health price target raised to $6 from $5 at Canaccord
TD Cowen Analyst forecast on DE:9EH
Charles Rhyee
TD Cowen
TD Cowen
€6.14→€7.01
Buy
178.34%
Upside
Reiterated
05/11/26
Analysts Offer Insights on Healthcare Companies: Evolent Health (NYSE: EVH), MoonLake Immunotherapeutics (NASDAQ: MLTX) and CAMP4 Therapeutics Corporation (NASDAQ: CAMP)
UBS Analyst forecast on DE:9EH
Kevin Caliendo
UBS
UBS
€4.38
Buy
73.96%
Upside
Reiterated
05/08/26
Evolent Health (EVH) Gets a Buy from UBS
KeyBanc Analyst forecast on DE:9EH
Matthew Gillmor CFA
KeyBanc
KeyBanc
―
Hold
―
Reiterated
05/08/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Evolent Health (NYSE: EVH), Zoetis (NYSE: ZTS) and ICU Medical (NASDAQ: ICUI)
BMO Capital Analyst forecast on DE:9EH
Sean Dodge
BMO Capital
BMO Capital
€3.07→€5.26
Buy
108.75%
Upside
Reiterated
05/08/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Needham Analyst forecast on DE:9EH
Matthew Shea
Needham
Needham
€3.51→€4.38
Buy
73.96%
Upside
Reiterated
05/07/26
Analysts Are Bullish on These Healthcare Stocks: Prime Medicine, Inc. (PRME), Evolent Health (EVH)
Oppenheimer Analyst forecast on DE:9EH
Michael Wiederhorn
Oppenheimer
Oppenheimer
―
Buy
―
Reiterated
03/20/26
Oppenheimer Reaffirms Their Buy Rating on Evolent Health (EVH)
J.P. Morgan Analyst forecast on DE:9EH
John Stansel
J.P. Morgan
J.P. Morgan
€4.38
Buy
73.96%
Upside
Reiterated
03/03/26
Evolent Health (EVH) Receives a Buy from J.P. Morgan
BTIG Analyst forecast on DE:9EH
David Larsen
BTIG
BTIG
€8.77→€7.01
Buy
178.34%
Upside
Reiterated
02/25/26
Evolent Health: Conservative Guidance and Elevated Reserves Set the Stage for 2026 Margin Upside and Support a Buy Rating
Stephens Analyst forecast on DE:9EH
Jeffrey Garro
Stephens
Stephens
€6.14
Buy
143.54%
Upside
Reiterated
02/25/26
Evolent Health (EVH) Gets a Buy from Stephens
Citizens JMP Analyst forecast on DE:9EH
Constantine Davides
Citizens JMP
Citizens JMP
€9.64→€8.77
Buy
247.92%
Upside
Reiterated
01/06/26
Evolent Health price target lowered to $10 from $11 at CitizensEvolent Health price target lowered to $10 from $11 at Citizens
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
BBOTBridgeBio Oncology Therapeutics
AVBPArriVent BioPharma, Inc.
BTSGBrightSpring Health Services, Inc.
MLYSMineralys Therapeutics, Inc.
AMLXAmylyx Pharmaceuticals Inc
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Evolent Health

3 Months
Richard CloseCanaccord Genuity
Success Rate
26/47 ratings generated profit
55%
Average Return
+2.47%
Copying Richard Close's trades and holding each position for 3 Months would result in 55.32% of your transactions generating a profit, with an average return of +2.47% per trade.
1 Year
Richard CloseCanaccord Genuity
Success Rate
21/47 ratings generated profit
45%
Average Return
+9.34%
Copying Richard Close's trades and holding each position for 1 Year would result in 44.68% of your transactions generating a profit, with an average return of +9.34% per trade.
2 Years
Richard CloseCanaccord Genuity
Success Rate
20/47 ratings generated profit
43%
Average Return
+19.45%
Copying Richard Close's trades and holding each position for 2 Years would result in 42.55% of your transactions generating a profit, with an average return of +19.45% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

9EH Analyst Recommendation Trends

Rating
Mar 26
Apr 26
May 26
Jun 26
Jul 26
Strong Buy
8
7
2
1
1
Buy
9
8
13
11
11
Hold
3
3
3
4
4
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
20
18
18
16
16
In the current month, 9EH has received 12 Buy Ratings, 4 Hold Ratings, and 0 Sell Ratings. 9EH average Analyst price target in the past 3 months is 4.99.
Each month's total comprises the sum of three months' worth of ratings.

9EH Financial Forecast

9EH Earnings Forecast

Next quarter’s earnings estimate for 9EH is >-€0.01 with a range of -€0.03 to <€0.01. The previous quarter’s EPS was -€0.02. 9EH beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.81% of the time in the same period. In the last calendar year 9EH has Performed in-line its overall industry.
Next quarter’s earnings estimate for 9EH is >-€0.01 with a range of -€0.03 to <€0.01. The previous quarter’s EPS was -€0.02. 9EH beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.81% of the time in the same period. In the last calendar year 9EH has Performed in-line its overall industry.

9EH Sales Forecast

Next quarter’s sales forecast for 9EH is €523.26M with a range of €466.45M to €554.18M. The previous quarter’s sales results were €434.61M. 9EH beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 48.70% of the time in the same period. In the last calendar year 9EH has Performed in-line its overall industry.
Next quarter’s sales forecast for 9EH is €523.26M with a range of €466.45M to €554.18M. The previous quarter’s sales results were €434.61M. 9EH beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 48.70% of the time in the same period. In the last calendar year 9EH has Performed in-line its overall industry.

9EH Stock Forecast FAQ

What is DE:9EH’s average 12-month price target, according to analysts?
Based on analyst ratings, Evolent Health Inc.’s 12-month average price target is 4.99.
    What is DE:9EH’s upside potential, based on the analysts’ average price target?
    Evolent Health Inc. has 97.88% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Evolent Health Inc. a Buy, Sell or Hold?
          Evolent Health Inc. has a consensus rating of Moderate Buy, which is based on 7 buy ratings, 3 hold ratings and 0 sell ratings.
            What is Evolent Health Inc.’s share price target?
            The average share price target for Evolent Health Inc. is 4.99. This is based on 10 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is €7.01 ,and the lowest forecast is €2.63. The average share price target represents 97.88% Increase from the current price of €2.52.
              What do analysts say about Evolent Health Inc.?
              Evolent Health Inc.’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 10 Wall Streets Analysts.
                How can I buy shares of Evolent Health Inc.?
                To buy shares of DE:9EH, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.